
|Articles|October 1, 2003
Iris-claw phakic IOL found to be safe for treating hyperopia
Author(s)Cheryl Guttman
Stanford, CA-The phase III trial of the iris-claw phakic IOL (Artisan, Ophtec) for the treatment of hyperopia is now 2 years post- launch, and the short- and long-term results from the interim analyses are very encouraging, said Edward E. Manche, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5